Nov 3 (Reuters) – Kimberly-Clark said on Monday it will acquire Tylenol maker Kenvue (KVUE.N) in a deal valued at about $48.7 billion, creating a consumer goods giant.
Kenvue’s shares were up 18% in premarket trading. Kimberly-Clark said it would buy all of the outstanding shares of Kenvue common stock in a cash-and-stock transaction.
Sign up here.
Kenvue’s shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held.
That implies a per-share deal value of $21.01, or an equity value of $40.32 billion, according to Reuters calculations.
Reporting by Juveria Tabassum in Bengaluru; Editing by Arun Koyyur and Devika Syamnath
Our Standards: The Thomson Reuters Trust Principles.
